Abstract
Background:The efficacy of mepolizumab (MPZ), an anti-IL-5 antibody for eosinophilic granulomatosis with polyangiitis (EGPA), has been reported. MPZ was approved for relapsing or refractory EGPA in 2018. We have reported...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
